WW International announced it intends to use up to $10 million in cash to prepay part of its term loan at a discount through a voluntary solicitation of offers from term loan lenders. The solicitation is expected to commence on Tuesday, November 17, 2026 and close on Friday, November 20, 2026.
WW · Ww International, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 58%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jun 2025 to Nov 2026
Up next
Latest documents
Weight Watchers reported third quarter 2026 revenue of $152.9 million, down 11%, while clinical subscription revenue increased 48% to $38 million and adjusted EBITDA increased 21% to $51.7 million. Full-year revenue guidance narrowed to $625 million to $630 million.
WW International, Inc. reported revenue of $152.9 million for the three months ended September 30, 2026, down 11.2% from $172.1 million, while net income reached $15.1 million.
WW International reported Q3 revenue of $152.9 million, down 11% year-over-year, while Clinical Subscription Revenue grew 48% to $38.0 million. Net income reached $15.1 million and Adjusted EBITDA was $51.7 million.
WW International, Inc. and Stephen J. Bye agreed his appointment as President, Chief Executive Officer and director will take effect October 1, 2026. Felicia DellaFortuna and Jonathan Volkmann will leave the Interim Office of the Chief Executive upon its dissolution but retain their officer roles.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Weight Watchers reported positive net income, higher adjusted EBITDA, positive operating cash flow, reduced debt, clinical and CorePlus subscriber growth, and narrowed full-year guidance. Revenue and behavioral subscribers declined, clinical subscribers fell sequentially, adjusted gross margin was lower year over year, Q1 awareness gains did not persist, and marketing spending is expected to increase in Q4.
- + Clinical subscription revenue grew 48% year over year to $38 million and represented approximately 25% of total revenue. new
- + CorePlus enrollment in the GLP-1 Success Program more than doubled since January. new
- + Operating cash flow was positive at $32.3 million and total debt has been reduced by more than 70% since the financial reorganization. new
- + Full-year revenue and adjusted EBITDA guidance ranges were narrowed, with the lower ends raised. new
- + Adjusted EBITDA increased 21% year over year to $51.7 million and adjusted EBITDA margin improved to 33.8% from 24.9%. new
- − Clinical subscribers declined sequentially from 197,000 at the end of June to 174,000, and moderate sequential declines are expected in Q4. new
- − Awareness gains from the concentrated Q1 clinical marketing investment did not carry through the year as anticipated. new
- − Marketing spending is expected to increase modestly in Q4, and full-year marketing expense as a percentage of revenue is expected to rise versus 2025. new
- − Third-quarter revenue declined 11% year over year to $152.9 million. new
- − Behavioral subscription revenue declined 22% year over year to $113.9 million, primarily reflecting the smaller CORE subscriber base. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Behavioral Subscription Revenue | $113.92M | FY2026 Q3 | -21.5% |
|
|
|||
| Clinical Subscription Revenue | $38.04M | FY2026 Q3 | +47.6% |
|
|
|||
| Clinical Subscription Revenue (Constant Currency) | $38.04M | FY2026 Q3 | +47.6% |
|
|
|||
| Total Subscription Revenue | $151.96M | FY2026 Q3 | -11.1% |
|
|
|||
| Adjusted EBITDA non-GAAP | $39.8M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationEBITDA 41.2M (non-GAAP)
+0M Franchise rights acquired impairments
+0M Reorganization items, net
-4.6M Gain on extinguishment of debt
+0M Transaction costs
-0.2M Restructuring charges
+3.8M Executive related one-time costs
-0.4M Other
= Adjusted EBITDA 39.8M
|
|||
| Adjusted EBITDA Margin non-GAAP | 24.5% | Q2 2026 | — |
| Adjusted Gross Margin non-GAAP | 73.6% | Q2 2026 | — |
| Behavioral Subscription Revenue (Constant Currency) | $120.7M | Q2 2026 filing | — |
| Core+ End of Period Subscribers | 541K | Q2 2026 | — |
| End of Period Behavioral Subscribers | 2.29M | Six Months Ended June 30, 2026 | — |
| End of Period Clinical Subscribers | 197K | Six Months Ended June 30, 2026 | — |
| End of Period Subscribers | 2.49M | Six Months Ended June 30, 2026 | — |
| Incoming Behavioral Subscribers | 2.63M | Six Months Ended June 30, 2026 | — |
| Incoming Clinical Subscribers | 130K | Six Months Ended June 30, 2026 | — |
| Incoming Subscribers | 2.76M | Six Months Ended June 30, 2026 | — |
| Marketing expense as a percentage of Revenue | 29.5% | Q2 2026 | — |
| Monthly Behavioral Subscription Revenue Per Average Subscriber | $16.91 | Six Months Ended June 30, 2026 | — |
| Monthly Behavioral Subscription Revenue Per Average Subscriber (Constant Currency) | $16.92 | Q2 2026 filing | — |
| Monthly Clinical Subscription Revenue Per Average Subscriber | $75.13 | Six Months Ended June 30, 2026 | — |
| Monthly Clinical Subscription Revenue Per Average Subscriber (Constant Currency) | $67.55 | Q2 2026 filing | — |
| Monthly Subscription Revenue Per Average Subscriber | $20.76 | Six Months Ended June 30, 2026 | — |
| Monthly Subscription Revenue Per Average Subscriber (ARPU) growth | 10.2% | Q2 2026 | — |
| Monthly Subscription Revenue Per Average Subscriber (Constant Currency) | $20.8 | Q2 2026 filing | — |
| Monthly Subscription Revenues Per Average Subscriber | $20.9 | Three Months Ended June 30, 2026 | — |
| Total End of Period Subscribers | 2.5M | Q2 2026 | — |
| Total Subscription Revenue (Constant Currency) | $160.6M | Q2 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WW
this stock
Ww International, Inc.
|
$69.69M | -76.1% | +12.2% | — | 20.5% |
|
HCA
HCA Healthcare, Inc.
|
$99.34B | +1.9% | +7.1% | 15.8 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$31.59B | -2.2% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.95B | +32.4% | +0.9% | 7.6 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.11B | +25.9% | +10.5% | 20.9 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 24
WW International announced it intends to use up to $10 million in cash to prepay part of its term loan at a discount through a voluntary solicitation of offers from term loan lenders. The solicitation is expected to commence on Tuesday, November 17, 2026 and close on Friday, November 20, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WW | -32.8% | -48.3% | -56.4% | -53.2% | -76.1% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -24.2% | -39.0% | -47.2% | -44.5% | -77.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.